We bring decades of experience in clinical research, specializing in abuse potential, abuse deterrence, clinical pharmacology, and early-phase drug development. Our team has designed and evaluated over 300 Phase 1 studies across multiple therapeutic areas, including substance use disorder, pain, epilepsy, anxiety, depression, and potential neurodegenerative disorders
Our unparalleled expertise in abuse liability assessment is built on decades of experience, combining ongoing, indepth dialogue with the FDA and work across a broad range of drug development programs. This dual perspective has given us a comprehensive understanding of the regulatory landscape and industry best practices, allowing us to support your nonclinical and clinical research with fully integrated scientific, regulatory, and operational input and documentation.
